{
    "clinical_study": {
        "@rank": "4798", 
        "acronym": "CHAT Pilot", 
        "arm_group": [
            {
                "arm_group_label": "Rosuvastatin", 
                "arm_group_type": "Experimental", 
                "description": "Rosuvastatin 40 mg via nasogastric tube then 20 mg po or via nasogastric tube daily for 14 days or until hospital discharge Placebo is identical capsule with no active drug\nBoth are crushed for administration"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Identical drug vehicle with no active agent"
            }
        ], 
        "brief_summary": {
            "textblock": "The CHAT Pilot Trial is designed to compare rosuvastatin against placebo in patients with\n      suspected H1N1.  The pilot study will assess the feasibility of our clinical protocols, and\n      study procedures."
        }, 
        "brief_title": "Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial", 
        "completion_date": {
            "#text": "August 2010", 
            "@type": "Actual"
        }, 
        "condition": "H1N1 Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "This trial is a pilot study to assess the feasibility and acceptability of a double blind\n      randomized controlled trial (RCT) evaluating the efficacy of rosuvastatin as adjuvant\n      therapy for H1N1 influenza"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Critically ill adult patients > 16 years of age admitted to an adult ICU for any\n             reason with suspected, probable or confirmed novel swine origin influenza A/H1N1\n             infection\n\n          -  Requiring mechanical ventilation (invasive or non-invasive)\n\n          -  Receiving antiviral therapy (any medication at any dose and for any intended\n             duration) for < 72 hours\n\n          -  Clinicians must have a 'moderate', 'high' or 'moderate to high' index of suspicion\n             for H1N1\n\n        Exclusion Criteria:\n\n          -  Age < 16 years\n\n          -  Do not resuscitate or re-intubate order documented on chart or anticipated withdrawal\n             of life support\n\n          -  Weight < 40 kg\n\n          -  Unable to receive or unlikely to absorb enteral study drug (e.g. incomplete or\n             complete bowel obstruction, intestinal ischemia, infarction, short bowel syndrome)\n\n          -  Rosuvastatin specific exclusions:\n\n               1. Already receiving a statin (Atorvastatin, Lovastatin, Simvastatin, Pravastatin,\n                  Rosuvastatin)\n\n               2. Allergy or intolerance to statins\n\n               3. Receiving niacin, fenofibrate, cyclosporine, gemfibrozil, lopinavir, ritonavir\n                  or planned use of oral contraceptives or estrogen therapy during the ICU stay\n\n               4. CK exceeds 10 times ULN or ALT exceeds 8 times the ULN\n\n          -  Severe chronic liver disease (Child-Pugh Score 11-15) (see Appendix 6)\n\n          -  Previous enrolment in this trial\n\n          -  Pregnancy or breast feeding\n\n          -  At the time of enrolment, patients must not have received >72 hours of antiviral\n             therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798602", 
            "org_study_id": "CCCTG"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rosuvastatin", 
                "description": "Tablet crushed for administration via feeding tube", 
                "intervention_name": "Rosuvastatin or identical placebo", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Crestor", 
                    "Placebo"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Identical placebo for rosuvastatin", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rosuvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "H1N1", 
            "Rosuvastatin"
        ], 
        "lastchanged_date": "February 22, 2013", 
        "link": [
            {
                "description": "International Forum for Acute Care Trialists Website", 
                "url": "http://www.infactglobal.org"
            }, 
            {
                "description": "Canadian Critical Care Trials Group", 
                "url": "http://www.ccctg.ca"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M5B 1W8"
                }, 
                "name": "St. Michael's Hospital"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "This was a pilot study whose primary goal was to evaluate the feasibility of patient recruitment during an emerging pandemic", 
            "measure": "Proportion of eligible patients enrolled in the CHAT study", 
            "safety_issue": "No", 
            "time_frame": "Over 6 month period or during H1N1 pandemic"
        }, 
        "reference": {
            "PMID": "21388549", 
            "citation": "Burns KE, Chant C, Smith O, Cuthbertson B, Fowler R, Cook DJ, Kruger P, Webb S, Alhashemi J, Dominguez-Cherit G, Zala C, Rubenfeld GD, Marshall JC. A Canadian Critical Care Trials Group project in collaboration with the international forum for acute care trialists - Collaborative H1N1 Adjuvant Treatment pilot trial (CHAT): study protocol and design of a randomized controlled trial. Trials. 2011 Mar 9;12:70. doi: 10.1186/1745-6215-12-70."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798602"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Adherence to the medication administration regimen as outlined in the study protocol.", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Proportion of completed primary and secondary endpoints for the planned full CHAT trial that are collected.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "The number of study withdrawals due to administration of open label statins and withdrawals of consent.", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days or until hospital discharge"
            }, 
            {
                "measure": "Recruitment rates by consent model.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Canadian Critical Care Trials Group", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Canadian Institutes of Health Research  (CIHR)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Physicians' Services Incorporated Foundation", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Public Health Agency of Canada (PHAC)", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Canadian Critical Care Trials Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013", 
        "why_stopped": "H1N1 pandemic concluded"
    }
}